Last update 17 Feb 2026
CanWell Pharma Co., Ltd.

CanWell Pharma Co., Ltd.

Holding Company|2018|Guangdong Sheng, China|
www.canwellbiotech.com

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Urogenital Diseases
Small molecule drug
Therapeutic vaccine
Small molecule-drug conjugates

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms9
Infectious Diseases4
Immune System Diseases2
Hemic and Lymphatic Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Prophylactic vaccine3
Small molecule drug2
Therapeutic vaccine2
Biological products1
Antibody drug conjugate (ADC)1
Top 5 TargetCount
TLR7(Toll like receptor 7)2
HER2(Receptor tyrosine-protein kinase erbB-2)1
TLR(Toll-like receptor)1

Related

12
Drugs associated with CanWell Pharma Co., Ltd.
CAN-1012
Target
TLR7
Mechanism
TLR7 agonists
Active Org.
IriSys, Inc. [+1]
Originator Org.
CanWell Pharma Co., Ltd.CanWell Pharma Co., Ltd.
Active Indication
Breast Cancer [+16]
Inactive Indication
Neoplasm Metastasis
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Autophagosome vaccine (UbiVac)
Target
TLR
Mechanism
TLR agonists [+1]
Active Org.
UbiVac, Inc.UbiVac, Inc. [+1]
Originator Org.
UbiVac, Inc.UbiVac, Inc.
Active Indication
Prostatic Cancer [+8]
Inactive Indication
Advanced Prostate Carcinoma [+4]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
CAN102
Target
TLR7
Mechanism
TLR7 agonists
Active Org.
CanWell Pharma Co., Ltd.CanWell Pharma Co., Ltd.
Originator Org.
CanWell Pharma Co., Ltd.CanWell Pharma Co., Ltd.
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with CanWell Pharma Co., Ltd.
NCT07408856
/ Not yet recruitingPhase 1IIT
A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Oral Epithelial Dysplasia, Ductal Carcinoma in Situ, and Lobular Carcinoma in Situ
NCT06410703
/ RecruitingPhase 1/2
A Phase Ib/IIa, Dose Escalation, Open-Label Study of Intratumoral CAN1012 Combined With PD-1 in Patients With Unresectable or Metastatic Advanced Solid Tumors
NCT06332430
/ RecruitingPhase 1
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors.
100 Clinical Results associated with CanWell Pharma Co., Ltd.
Login to view more data
0 Patents (Medical) associated with CanWell Pharma Co., Ltd.
Login to view more data
100 Deals associated with CanWell Pharma Co., Ltd.
Login to view more data
100 Translational Medicine associated with CanWell Pharma Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
7
1
Preclinical
Phase 1
3
1
Phase 2
Other
4
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free